Detailed phase 3 data show retatrutide lowered body weight and A1C over 80 weeks for patients with diabetes and obesity.

In a rapidly evolving diabetes and obesity management landscape, Brian Smith, PharmD, discusses approaches that are helping patients maximize their outcomes on GLP-1 therapy.

In this episode, our hosts examine the expanding role of incretin therapies in children and adolescents with obesity and type 2 diabetes.

GLP-1 adherence requires integrated care teams, administrative technology, and proactive clinical support to tackle complex challenges.

Orforglipron lowered A1C and body weight more than oral semaglutide 25 mg at 52 weeks, but the estimate comes from an indirect comparison.

Brian Smith, PharmD, explains how direct-to-consumer GLP-1 pathways broaden initial access but endanger long-term patient adherence.

The analysis is not a head-to-head trial, and the weight loss gap reached statistical significance under 1 of 2 estimands.

A claims analysis of 2031 patients aged 10 to 17 years found that nutrition counseling was infrequent and often began months after treatment started.